Instil Bio, Inc. (TIL) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $795.00K; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $795.00K | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $795.00K |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 90.33M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 795.00K USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | Other Liabilities, Current |
| Reported other noncurrent obligations | 0.00 USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $2.23M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $795.00K | (m) | (m) | (m) | $90.33M | (m) | (m) | (m) | $0.00 | (m) |
| 2026-03-31 | (m) | $793.00K | (m) | (m) | (m) | $89.73M | (m) | (m) | (m) | $8.00K | (m) |
| 2025-12-31 | (m) | $779.00K | (m) | (m) | (m) | $89.66M | (m) | (m) | (m) | $8.00K | (m) |
| 2025-09-30 | (m) | $928.00K | (m) | (m) | (m) | $91.35M | (m) | (m) | (m) | $88.00K | (m) |
| 2025-06-30 | (m) | $523.00K | (m) | (m) | (m) | $99.32M | (m) | (m) | (m) | $90.00K | (m) |
| 2025-03-31 | (m) | $286.00K | (m) | (m) | (m) | $92.54M | (m) | (m) | (m) | $85.00K | (m) |
| 2024-12-31 | (m) | $659.00K | (m) | $0.00 | (m) | $94.13M | (m) | (m) | (m) | $83.00K | (m) |
| 2024-09-30 | (m) | $1.20M | (m) | $107.00K | (m) | $96.23M | (m) | (m) | (m) | $8.00K | (m) |
| 2024-06-30 | (m) | $1.22M | (m) | $143.00K | (m) | $99.30M | (m) | (m) | (m) | $8.00K | (m) |
| 2024-03-31 | (m) | $1.23M | (m) | $145.00K | (m) | $100.48M | (m) | (m) | (m) | $43.00K | (m) |
| 2023-12-31 | (m) | $1.21M | (m) | $190.00K | (m) | $99.80M | (m) | (m) | (m) | $80.00K | (m) |
| 2023-09-30 | (m) | $1.65M | (m) | $324.00K | (m) | $106.25M | (m) | (m) | (m) | $115.00K | (m) |
| 2023-06-30 | (m) | $2.16M | (m) | $339.00K | (m) | $111.79M | (m) | (m) | (m) | $162.00K | (m) |
| 2023-03-31 | (m) | $1.35M | (m) | $539.00K | (m) | $116.02M | (m) | (m) | (m) | $196.00K | (m) |
| 2022-12-31 | (m) | $2.36M | (m) | $592.00K | (m) | $118.52M | (m) | (m) | (m) | $332.00K | (m) |
| 2022-09-30 | (m) | $5.33M | (m) | $933.00K | (m) | $122.15M | (m) | (m) | (m) | $375.00K | (m) |
| 2022-06-30 | (m) | $5.79M | (m) | $891.00K | (m) | $110.20M | (m) | (m) | (m) | $345.00K | (m) |
| 2022-03-31 | (m) | $7.71M | (m) | $643.00K | (m) | $56.38M | (m) | (m) | (m) | $20.00K | (m) |
| 2021-12-31 | (m) | $5.57M | (m) | $386.00K | (m) | $54.78M | (m) | (m) | (m) | $20.00K | (m) |
| 2021-09-30 | (m) | $5.25M | (m) | $234.00K | (m) | $45.98M | (m) | (m) | (m) | $1.54M | (m) |
| 2021-06-30 | (m) | $5.22M | (m) | $193.00K | (m) | $37.20M | (m) | (m) | (m) | $1.11M | (m) |
| 2021-03-31 | (m) | $3.73M | (m) | $171.00K | (m) | $30.99M | (m) | (m) | (m) | $306.00K | (m) |
| 2020-12-31 | (m) | $3.50M | (m) | $281.00K | (m) | $26.64M | (m) | (m) | (m) | $0.00 | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |